Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

Hyperphosphataemia is common in patients with nephrogenic systemic fibrosis (NSF). NSF has been linked to administration of gadolinium (Gd) chelates (GCs) and elevated serum phosphate levels accelerate the release of Gd from linear, non‐ionic GCs but not macrocyclic GCs. Hence, we determined whether hyperphosphataemia is a cofactor or risk factor for NSF by investigating the role of hyperphosphataemia in renally impaired rats.

[1]  M. Port,et al.  Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.

[2]  M. Perazella,et al.  Imaging Patients With Kidney Disease: How Do We Approach Contrast-Related Toxicity? , 2011, The American journal of the medical sciences.

[3]  C. Robic,et al.  Clinical, Biological, and Skin Histopathologic Effects of Ionic Macrocyclic and Nonionic Linear Gadolinium Chelates in a Rat Model of Nephrogenic Systemic Fibrosis , 2011, Investigative radiology.

[4]  H. Ellinger-Ziegelbauer,et al.  The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats , 2011, Investigative radiology.

[5]  J. Varani,et al.  Fibroblast Response to Gadolinium: Role for Platelet-Derived Growth Factor Receptor , 2010, Investigative radiology.

[6]  Shawn Cowper,et al.  Nephrogenic systemic fibrosis , 2010, F1000 medicine reports.

[7]  R. Swartz,et al.  Responses of Human Skin in Organ Culture and Human Skin Fibroblasts to a Gadolinium-Based MRI Contrast Agent: Comparison of Skin From Patients With End-Stage Renal Disease and Skin From Healthy Subjects , 2010, Investigative radiology.

[8]  S. George,et al.  Synchrotron X‐ray analyses demonstrate phosphate‐bound gadolinium in skin in nephrogenic systemic fibrosis , 2010, The British journal of dermatology.

[9]  S. Morcos,et al.  Nephrogenic Gadolinium Biodistribution and Skin Cellularity Following a Single Injection of Omniscan in the Rat , 2010, Investigative radiology.

[10]  J. Quinn,et al.  Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. , 2010, Radiology.

[11]  J. Vickers,et al.  The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. , 2010, Journal of the American Academy of Dermatology.

[12]  T. Gambichler,et al.  Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  J. L. Abraham,et al.  Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation. , 2010, The American Journal of dermatopathology.

[14]  Kui Wang,et al.  Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells , 2010, JBIC Journal of Biological Inorganic Chemistry.

[15]  C. Robic,et al.  Role of thermodynamic and kinetic parameters in gadolinium chelate stability , 2009, Journal of magnetic resonance imaging : JMRI.

[16]  J. L. Abraham,et al.  Gadolinium‐Induced Nephrogenic Systemic Fibrosis Is Associated with Insoluble Gd Deposits in Tissues: In Vivo Transmetallation Confirmed by Microanalysis , 2009, Journal of cutaneous pathology.

[17]  R. Gomer,et al.  Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation , 2009, Journal of magnetic resonance imaging : JMRI.

[18]  T. Steger-Hartmann,et al.  The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. , 2009, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[19]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[20]  D. Løvhaug,et al.  Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.

[21]  R. Swartz,et al.  Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts , 2009, Investigative radiology.

[22]  Mei Wang,et al.  Hyperphosphatemia-induced hyperparathyroidism in 5/6 nephrectomized rats: development of a new animal model. , 2008, Chinese Medical Journal.

[23]  T. Frenzel,et al.  Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.

[24]  Martin R Prince,et al.  Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.

[25]  T. Frenzel,et al.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.

[26]  B. Kelly,et al.  Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. , 2008, Journal of the American Academy of Dermatology.

[27]  D. Broome,et al.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.

[28]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[29]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[30]  J. Topf,et al.  Nephrogenic Fibrosing Dermopathy , 2008, TheScientificWorldJournal.

[31]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[32]  L. Skov,et al.  Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long‐term persistence in nephrogenic systemic fibrosis , 2007, The British journal of dermatology.

[33]  R. Bucala.  Circulating fibrocytes: cellular basis for NSF. , 2008, Journal of the American College of Radiology : JACR.

[34]  Frank J Rybicki,et al.  Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.

[35]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  A. Peak,et al.  Risk Factors for Developing Gadolinium-Induced Nephrogenic Systemic Fibrosis , 2007, The Annals of pharmacotherapy.

[37]  Charu Thakral,et al.  Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. , 2007, Contrast media & molecular imaging.

[38]  M. D. de Broe,et al.  Role of Dietary Phosphorus and Degree of Uremia in the Development of Renal Bone Disease in Rats , 2007, Renal failure.

[39]  S. Cowper.  Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. , 2007, Advances in dermatology.

[40]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  J. Coladonato,et al.  Control of hyperphosphatemia among patients with ESRD. , 2005, Journal of the American Society of Nephrology : JASN.

[42]  M. Port,et al.  How to Compare the Efficiency of Albumin-Bound and Nonalbumin-Bound Contrast Agents In Vivo: The Concept of Dynamic Relaxivity , 2005, Investigative radiology.

[43]  Oprs Alert.  Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .

[44]  A. Mauviel,et al.  TGF-β-induced SMAD signaling and gene regulation : consequences for extracellular matrix remodeling and wound healing , 2004 .

[45]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[46]  Ellen M. Leiferman,et al.  Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism. , 2004, Kidney international.

[47]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[48]  A. Mauviel,et al.  TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. , 2004, Journal of dermatological science.

[49]  R. Swartz,et al.  Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.

[50]  R. Nissi,et al.  Prolyl 4-Hydroxylase , 2003 .

[51]  T. Singer,et al.  Comparison of clinical pathology parameters with two different blood sampling techniques in rats: retrobulbar plexus versus sublingual vein , 2000, Laboratory animals.

[52]  V. Lorusso,et al.  Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). , 1999, Journal of computer assisted tomography.

[53]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[54]  A. Fulcher,et al.  Thoracopancreatic fistula: clinical and imaging findings. , 1999, Journal of computer assisted tomography.

[55]  Philip R. Cohen,et al.  Dermatopathologic advances in clinical research. The expression of antibody to CD34 in mucocutaneous lesions. off. , 1997, Dermatologic clinics.

[56]  B. Nickoloff.  The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi's sarcoma. , 1991, Archives of dermatology.

[57]  Leroy Ec,et al.  Cytokines and human fibrosis. , 1990 .

[58]  E. Leroy,et al.  Cytokines and human fibrosis. , 1990, European cytokine network.

[59]  L. Matrisian,et al.  Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.